PMID- 23279037
OWN - NLM
STAT- MEDLINE
DCOM- 20130701
LR  - 20151119
IS  - 1440-1754 (Electronic)
IS  - 1034-4810 (Linking)
VI  - 49
IP  - 1
DP  - 2013 Jan
TI  - Atrial natriuretic peptide as a marker of heart failure in children with left 
      ventricular volume overload.
PG  - 43-7
LID - 10.1111/jpc.12012 [doi]
AB  - AIM: To evaluate the role of atrial natriuretic peptide (ANP) in differentiating 
      the aetiology of heart failure in children with left ventricular (LV) volume 
      overload. METHODS: The study was conducted on 48 patients with LV volume overload 
      (G one: rheumatic heart disease in failure; G2: compensated rheumatic heart 
      disease; G3: congenital left to right shunt; and G4: dilated cardiomyopathy). 
      Twelve healthy children served as a control group. New York Heart Association 
      (NYHA) class, LV dimensions and functions using Vivid 7 dimensions were 
      evaluated. Serum ANP was measured using the ELISA technique, before and 3 months 
      after treatment with angiotensin converting enzyme inhibitor. RESULTS: ANP was 
      raised in all patients as compared to controls (G one: 28.33 +/- 5.78, G2: 26.5 +/- 
      4.11, G3: 28.5 +/- 6.6, G4: 29.25 +/- 4.5 pg/mL, control group: 5.54 +/- 1.4 pg/mL, P < 
      0.001 for all) and varied significantly between different NYHA classes regardless 
      of the underlying cardiac lesion. It was significantly higher in group 1 than 2 
      (P < 0.05). It decreased significantly after treatment (G1: 15.3 +/- 5.3, G2: 10.7 
      +/- 2.5, G3: 11.5 +/- 3.8, G4: 15.7 +/- 10.7 pg/mL, P < 0.001). The rate of change of 
      ANP correlated with that of LV end diastolic diameter (r = 0.3, P < 0.05) 
      irrespective of the underlying cause. CONCLUSION: ANP increases in cases of LV 
      volume overload irrespective of the aetiology of heart failure. It can 
      differentiate between children in quiescent state from those in clinical failure 
      even in the absence of echocardiographically detectable systolic dysfunction. 
      Furthermore, it can monitor LV remodelling with treatment.
CI  - (c) 2012 The Authors. Journal of Paediatrics and Child Health (c) 2012 Paediatrics 
      and Child Health Division (Royal Australasian College of Physicians).
FAU - Kotby, Alyaa A
AU  - Kotby AA
AD  - Faculty of Medicine, Department of Pediatric, Ain Shams University, Cairo, Egypt.
FAU - Taman, Khaled H
AU  - Taman KH
FAU - Sedky, Heba Tallah A
AU  - Sedky HT
FAU - Habeeb, Nevin M M
AU  - Habeeb NM
FAU - El-Hadidi, Eman S
AU  - El-Hadidi ES
FAU - Yosseif, Hanan S
AU  - Yosseif HS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20121228
PL  - Australia
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Biomarkers)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
MH  - Adolescent
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Atrial Natriuretic Factor/*blood
MH  - Biomarkers/blood
MH  - Cardiomyopathy, Dilated/blood/*complications/drug therapy
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - Ductus Arteriosus, Patent/blood/*complications
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/blood/*diagnosis/drug therapy/etiology
MH  - Heart Septal Defects/blood/*complications
MH  - Heart Valve Diseases/blood/complications
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Prospective Studies
MH  - Rheumatic Heart Disease/blood/*complications/drug therapy
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/blood/*complications/diagnosis
MH  - Ventricular Remodeling
EDAT- 2013/01/03 06:00
MHDA- 2013/07/03 06:00
CRDT- 2013/01/03 06:00
PHST- 2012/02/14 00:00 [accepted]
PHST- 2013/01/03 06:00 [entrez]
PHST- 2013/01/03 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - 10.1111/jpc.12012 [doi]
PST - ppublish
SO  - J Paediatr Child Health. 2013 Jan;49(1):43-7. doi: 10.1111/jpc.12012. Epub 2012 
      Dec 28.